NCT00615667

Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 14 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Exploring the efficacy and safety of Tacrolimus on refractory nephrotic syndrome ; Acquiring the experience of Tacrolimus on the treatment of refractory nephrotic syndrome in Chinese patients.

Conditions

• Kidney Diseases
• Nephrotic Syndrome
• Tacrolimus

Interventions

Type	Name	Description
DRUG	tacrolimus (FK506)	Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;

Timeline

• Start date: 2006-06-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2008-02-14
• Last updated: 2016-04-20